Advertisement

Skeletal Radiology

, Volume 33, Issue 9, pp 524–530 | Cite as

Carbon-11-methionine positron emission tomography imaging of chordoma

  • Hong Zhang
  • Kyosan YoshikawaEmail author
  • Katsumi Tamura
  • Kenji Sagou
  • Mei Tian
  • Tetsuya Suhara
  • Susumu Kandatsu
  • Kazutoshi Suzuki
  • Shuji Tanada
  • Hirohiko Tsujii
Article

Abstract

Objective

Chordoma is a rare malignant bone tumor that arises from notochord remnants. This is the first trial to investigate the utility of 11C-methionine (MET) positron emission tomography (PET) in the imaging of chordoma before and after carbon-ion radiotherapy (CIRT).

Design and patients

Fifteen patients with chordoma were investigated with MET-PET before and after CIRT and the findings analyzed visually and quantitatively. Tumor MET uptake was evaluated by tumor-to-nontumor ratio (T/N ratio).

Results

In 12 (80%) patients chordoma was clearly visible in the baseline MET-PET study with a mean T/N ratio of 3.3±1.7. The MET uptake decreased significantly to 2.3±1.4 after CIRT (P<0.05). A significant reduction in tumor MET uptake of 24% was observed after CIRT. Fourteen (93%) patients showed no local recurrence after CIRT with a median follow-up time of 20 months.

Conclusion

This study has demonstrated that MET-PET is feasible for imaging of chordoma. MET-PET could provide important tumor metabolic information for the therapeutic monitoring of chordoma after CIRT.

Keywords

Chordoma 11C-methionine PET Carbon ion radiotherapy Diagnosis 

References

  1. 1.
    Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10:291-296.CrossRefPubMedGoogle Scholar
  2. 2.
    Mindell ER. Chordoma. J Bone Joint Surg Am 1981; 63:501–505.PubMedGoogle Scholar
  3. 3.
    Breteau N, Demasure M, Lescrainier J, Sabbattier R, Michenet P. Sacrococcygeal chordomas: potential role of high LET therapy. Recent Results Cancer Res 1998; 150:148-155.PubMedGoogle Scholar
  4. 4.
    Watkins L, Khudados ES, Kaleoglu M, Revesz T, Sacares P, Crockard HA. Skull base chordomas: a review of 38 patients, 1958–88. Br J Neurosurg 1993; 7:241-248.PubMedGoogle Scholar
  5. 5.
    Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. Neurosurgery 1995; 36:887-897.PubMedGoogle Scholar
  6. 6.
    Al-Mefty O, Borba LA. Skull base chordomas: a management challenge. J Neurosurg 1997; 86:182-189.PubMedGoogle Scholar
  7. 7.
    Krayenbuhl H, Yasargil MG. Cranial chordomas. Progr Neurol Surg 1975; 6:380–434.Google Scholar
  8. 8.
    Benk V, Liebsch NJ, Munzenrider JE, Efird J, McManus P, Suit H. Base of skull and cervical spine chordomas in children treated by high-dose irradiation. Int J Radiat Oncol Biol Phys 1995; 31:577–581.CrossRefPubMedGoogle Scholar
  9. 9.
    Castro JR, Collier JM, Petti PL, et al. Charged particle radiotherapy for lesions encircling the brain stem or spinal cord. Int J Radiat Oncol Biol Phys 1989; 17:477–484.PubMedGoogle Scholar
  10. 10.
    Kamada T, Tsujii H, Tsuji H, et al. Working Group for the Bone and Soft Tissue Sarcomas. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol 2002; 20:4466–4471.CrossRefPubMedGoogle Scholar
  11. 11.
    Gambhir SS. Molecular imaging of cancer with positron emission tomography. Natl Rev Cancer 2002; 2:683–693.CrossRefGoogle Scholar
  12. 12.
    Zhang H, Tian M, Oriuchi N, Higuch, T, Tanada S, Endo K. Oncological diagnosis using positron coincidence gamma camera with fluorodeoxyglucose in comparison with dedicated PET. Br J Radiol 2002; 75:409–416.PubMedGoogle Scholar
  13. 13.
    Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972―1980.PubMedGoogle Scholar
  14. 14.
    Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32:1485–1490.PubMedGoogle Scholar
  15. 15.
    Hautzel H, Muller-Gartne, HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med 1997; 38:1384–1386.PubMedGoogle Scholar
  16. 16.
    Hoffman RM. Unbalanced transmethylation and the perturbation of the differentiated state leading to cancer. Bioessays 1990; 12:163–166.PubMedGoogle Scholar
  17. 17.
    Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003; 30:868―873.PubMedGoogle Scholar
  18. 18.
    Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36:484–492.PubMedGoogle Scholar
  19. 19.
    Schaider H, Haberkorn U, Berger MR, Oberdorfer F, Morr I, van Kaick G. Application of alpha-aminoiosbutyric acid,l-methionine, thymidine and 2-fluoro-2-d-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. Eur J Nucl Med 1996; 23:55–60.PubMedGoogle Scholar
  20. 20.
    Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-d-glucose, l-methionine, thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993; 34:773–779.PubMedGoogle Scholar
  21. 21.
    Kubota K, Ishiwata K, Kubota R, et al. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine,l-[methyl-14C] methionine, [6-3H]thymidine, and gallium-67. J Nucl Med 1991; 32:2118–2123.PubMedGoogle Scholar
  22. 22.
    Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose andl-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1‘995; 36:252–258.Google Scholar
  23. 23.
    Stern PH, Hoffman RM. Elevated overall rates of transmethylation in cell lines from diverse human tumors. In Vitro 1984; 20:663–670.PubMedGoogle Scholar
  24. 24.
    Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol 1984; 119:29–34.PubMedGoogle Scholar
  25. 25.
    Wheatley DN. On the problem of linear incorporation of amino acids into cell protein. Experientia 1982; 38:818–820.PubMedGoogle Scholar
  26. 26.
    Weiss SW. WHO international histological classification of tumours. Histological typing of soft tissue tumours, 2nd edn. Berlin Heidelberg New York: Springer, 1994.Google Scholar
  27. 27.
    Langstrom B, Antoni G, Gullberg P, et al. Synthesis ofl-and d-[methy-11C]methionine. J Nucl Med 1987; 19:1037–1040.Google Scholar
  28. 28.
    Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Joensuu H. Uptake of11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991; 64:1121―1124.PubMedGoogle Scholar
  29. 29.
    Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(Suppl 2):57–63.Google Scholar
  30. 30.
    Hug EB, Loredo LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999; 91:432–439.PubMedGoogle Scholar
  31. 31.
    Verstraete KL, Lang P. Post-therapeutic magnetic resonance imaging of bone tumors. Top Magn Reson Imaging 1999; 10:237–246.PubMedGoogle Scholar
  32. 32.
    Fletcher BD. Effects of pediatric cancer therapy on the musculoskeletal system. Pediatr Radiol 1997; 27:623–636.CrossRefPubMedGoogle Scholar
  33. 33.
    Murphy WA Jr. Imaging bone tumors in the 1990s. Cancer 1991; 67:1169–1176.PubMedGoogle Scholar
  34. 34.
    Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 2002; 94:3277–3284.CrossRefPubMedGoogle Scholar
  35. 35.
    Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14:700–708.PubMedGoogle Scholar
  36. 36.
    Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [11C]-l-methionine positron emission tomography. Clin Cancer Res 2001; 7:2269―2276.PubMedGoogle Scholar
  37. 37.
    Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res 1990; 50:3413―3415.PubMedGoogle Scholar

Copyright information

© ISS 2004

Authors and Affiliations

  • Hong Zhang
    • 1
    • 2
  • Kyosan Yoshikawa
    • 3
    Email author
  • Katsumi Tamura
    • 3
  • Kenji Sagou
    • 3
  • Mei Tian
    • 1
  • Tetsuya Suhara
    • 1
  • Susumu Kandatsu
    • 3
  • Kazutoshi Suzuki
    • 1
  • Shuji Tanada
    • 1
  • Hirohiko Tsujii
    • 4
  1. 1.Department of Medical ImagingNational Institute of Radiological SciencesChibaJapan
  2. 2.Department of Medical Imaging, Research Center Hospital for Charged Particle TherapyNational Institute of Radiological SciencesChibaJapan
  3. 3.Clinical Diagnosis SectionNational Institute of Radiological SciencesChibaJapan
  4. 4.Research Center for Charged Particle TherapyNational Institute of Radiological SciencesChibaJapan

Personalised recommendations